2.0
May 16, 2013
Recommend
CEO approval
Business Outlook
Pros
The chance to work with very talented engineers and scientists in a variety of fields.
Cons
Due to a series of setbacks and strategic misteps, Roche has recently terminated internal development of all next generation sequencing, and laid off 2/3 of R&D. Morale is very low. No compelling new direction has been presented to the people who remain in R&D.